BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tafasitamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tafasitamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04161248-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tafasitamab: Phase 1 readout est. (NCT04161248)
DESCRIPTION:Tafasitamab\, phase 1.\nStudy: Phase I Master Protocol of Novel
  Combination Therapy for Patients With Relapsed or Refractory Aggressive B
 -Cell Lymphoma\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04161248
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05351593-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tafasitamab: Phase 1/2 readout est. (NCT05351593)
DESCRIPTION:Tafasitamab\, phase 1/2.\nStudy: Tafasitamab Plus Lenalidomide 
 in Relapsed CNS Lymphoma\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05351593
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760156-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06760156)
DESCRIPTION:Tafasitamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Tafasita
 mab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Ly
 m\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06760156
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05943496-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tafasitamab: Phase 1 readout est. (NCT05943496)
DESCRIPTION:Tafasitamab\, phase 1.\nStudy: Tafasitamab\, Acalabrutinib\, an
 d Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocyt
 ic Leukemia and Small Lymphocytic Lymphoma\nEstimated primary completion: 
 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tafas
 itamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05943496
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT04978584)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and With Comb
 ination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Cen
 ter Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated primary co
 mpletion: 16 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tafasitamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04978584
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583071-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05583071)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Methotrexate\, Tafasitamab\, Len
 alidomide and Rituximab in Patients With PCNSL\nEstimated primary completi
 on: February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ta
 fasitamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05583071
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03930953-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Tafasitamab: Phase 1/2 readout est. (NCT03930953)
DESCRIPTION:Tafasitamab\, phase 1/2.\nStudy: A Safety and Preliminary Effic
 acy Study of CC-99282\, Alone and in Combination With Anti-lymphoma Agents
  in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NH
 L)\nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03930953
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05718869-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05718869)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Tafasitamab and Zanubrutinib for
  the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukem
 ia or Small Lymphocytic Lymphoma\, TaZA CLL Study\nEstimated primary compl
 etion: 27 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tafasitamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05718869
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615636-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270819
DTEND;VALUE=DATE:20270820
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05615636)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: A Phase II Trial of Mosunetuzuma
 b\, Polatuzumab\, Tafasitamab\, and Lenalidomide in Patients With Relapsed
  B-cell NHL\nEstimated primary completion: 19 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05615636
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465433-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270829
DTEND;VALUE=DATE:20270830
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06465433)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Extension Study to Provide Conti
 nued Treatment for Patients With Hematologic Malignancies Previously Enrol
 led in Studies With Tafasitamab\nEstimated primary completion: 29 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06465433
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04646395-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT04646395)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Study of Acalabrutinib and Tafas
 itamab in MZL Patients\nEstimated primary completion: 15 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04646395
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104565-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07104565)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Study to Assess the Safety and T
 olerability of Tafasitamab in Adult Participants With Primary Autoimmune B
 lood Cell Disorders\nEstimated primary completion: 23 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07104565
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225439-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tafasitamab: Phase 1 readout est. (NCT07225439)
DESCRIPTION:Tafasitamab\, phase 1\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for 
 Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)\n
 Estimated primary completion: December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07225439
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786040-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05786040)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Tafasitamab and Rituximab for Fr
 ont-Line Treatment of Post-Transplant Lymphoproliferative Disorder\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05786040
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029309-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Tafasitamab: Phase 1/2 readout est. (NCT06029309)
DESCRIPTION:Tafasitamab\, phase 1/2.\nStudy: Zanubrutinib and Tafasitamab i
 n Mantle Cell Lymphoma\nEstimated primary completion: 1 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06029309
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05366218-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tafasitamab: Phase 1/2 readout est. (NCT05366218)
DESCRIPTION:Tafasitamab\, phase 1/2.\nStudy: Tafasitamab (MOR00208) in Pedi
 atric Patients With Relapsed or Refractory Acute B Lineage Leukemia\nEstim
 ated primary completion: July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05366218
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tafasitamab: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Tafasitamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combin
 ation With Gemcitabine and Oxaliplatin Versus Rituximab in Combination Wit
 h Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse
  Large B-Cell Lymphoma\nEstimated primary completion: September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938619-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07938619)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Tafasitamab\, Lenalidomide\, Rituximab\, and Orelabrutinib for Patients Wi
 th Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary
  completion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tafasitamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07938619
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06434363-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tafasitamab: Phase 1/2 readout est. (NCT06434363)
DESCRIPTION:Tafasitamab\, phase 1/2.\nStudy: Phase I/II Study of AD-PluRece
 ptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients Wi
 th Autoimmune Disorders\nEstimated primary completion: 31 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06434363
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621406-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07621406)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Trans
 plantation Combined With Tafasitamab\, Lenalidomide\, and Standard Immunoc
 hemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07621406
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582159-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07582159)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Tafasitamab With Acalabrutinib a
 nd Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymp
 hocytic Lymphoma\nEstimated primary completion: 14 April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07582159
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07906080-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tafasitamab: Phase 1 readout est. (NCT07906080)
DESCRIPTION:Tafasitamab\, phase 1\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induce
 d Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide
  in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEs
 timated primary completion: 30 June 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07906080
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792825-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20290708
DTEND;VALUE=DATE:20290709
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT06792825)
DESCRIPTION:Tafasitamab\, phase 2\, Follicular Lymphoma.\nStudy: HM2023-43:
 Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive F
 L and MZL\nEstimated primary completion: 8 July 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06792825
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05890352)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Retur
 ned or Did Not Respond to Treatment\nEstimated primary completion: 1 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 90352
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910801-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05910801)
DESCRIPTION:Tafasitamab\, phase 2.\nStudy: Tafasitamab\, Lenalidomide and V
 enetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
 \nEstimated primary completion: 30 December 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05910801
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585747-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07585747)
DESCRIPTION:Tafasitamab\, phase 2\, Follicular Lymphoma.\nStudy: A Explorat
 ory Study on Untreated Follicular Lymphoma With Orelabrutinib\, Tafasitama
 b\, and Lenalidomide\nEstimated primary completion: 31 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07585747
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502872-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07502872)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 TPG: Tafasitamab\, Polatuzumab Vedotin\, and Glofitamab as First-line Ther
 apy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma\nEsti
 mated primary completion: 1 January 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07502872
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731789-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07731789)
DESCRIPTION:Tafasitamab\, phase 2\, Follicular Lymphoma.\nStudy: Tafasitama
 b and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma\n
 Estimated primary completion: 31 October 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07731789
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283679-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Tafasitamab: Phase 1/2 readout est. (NCT07283679)
DESCRIPTION:Tafasitamab\, phase 1/2.\nStudy: Trial of ONC-PluReceptor NK Ce
 lls With Epcoritamab and Tafasitamab for Patients With Recurrent or Refrac
 tory B-cell Non-Hodgkin Lymphoma\nEstimated primary completion: 30 Septemb
 er 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 3679
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126236-5647@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20311227
DTEND;VALUE=DATE:20311228
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07126236)
DESCRIPTION:Tafasitamab\, phase 2\, Large B-Cell Lymphoma.\nStudy: Response
 -adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy 
 of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma\n
 Estimated primary completion: 27 December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07126236
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
